Reuters -- Bumper sales of swine flu vaccine boosted GlaxoSmithKline’s first-quarter earnings by 17 percent, more than expected, and the drugmaker reassured investors it could absorb the cost of U.S. healthcare reform.
Reuters -- Bumper sales of swine flu vaccine boosted GlaxoSmithKline’s first-quarter earnings by 17 percent, more than expected, and the drugmaker reassured investors it could absorb the cost of U.S. healthcare reform.